Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways /
نام عام مواد
[Book]
نام نخستين پديدآور
Yosef Yarden, Moshe Elkabets, editors.
وضعیت نشر و پخش و غیره
محل نشرو پخش و غیره
Cham, Switzerland :
نام ناشر، پخش کننده و غيره
Springer,
تاریخ نشرو بخش و غیره
2018.
مشخصات ظاهری
نام خاص و کميت اثر
1 online resource
فروست
عنوان فروست
Resistance to targeted anti-cancer therapeutics ;
مشخصه جلد
volume 15
یادداشتهای مربوط به کتابنامه ، واژه نامه و نمایه های داخل اثر
متن يادداشت
Includes bibliographical references and index.
یادداشتهای مربوط به مندرجات
متن يادداشت
Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
بدون عنوان
0
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
یادداشتهای مربوط به سفارشات
منبع سفارش / آدرس اشتراک
Springer Nature
شماره انبار
com.springer.onix.9783319679327
ویراست دیگر از اثر در قالب دیگر رسانه
عنوان
Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways.